{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:06:30Z","timestamp":1790690790480,"version":"4.1.0"},"reference-count":72,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"NIH NCI","doi-asserted-by":"publisher","award":["R00CA286742"],"award-info":[{"award-number":["R00CA286742"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NIH NCI","doi-asserted-by":"publisher","award":["R35CA209859"],"award-info":[{"award-number":["R35CA209859"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NIH NCI","doi-asserted-by":"publisher","award":["R03CA290259"],"award-info":[{"award-number":["R03CA290259"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009730","name":"Stand Up To Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006019","name":"Van Andel Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006019","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bneo.2026.100243","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T22:18:52Z","timestamp":1778019532000},"page":"100243","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bone marrow immunosuppressive states associate with survival after guadecitabine and atezolizumab therapy in HMA-R\/R MDS"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9654-4448","authenticated-orcid":false,"given":"H. Josh","family":"Jang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Urrutia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9996-7155","authenticated-orcid":false,"given":"Andreas Due","family":"\u00d8rskov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anh Van","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1642-966X","authenticated-orcid":false,"given":"Hyeon Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth A.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyein","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3683-6286","authenticated-orcid":false,"given":"Ryan S.","family":"Burgos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin K.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Wegener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4060-6181","authenticated-orcid":false,"given":"Katelyn","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7909-2339","authenticated-orcid":false,"given":"Marie","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Sheridan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary H.","family":"Ramjan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0630-8589","authenticated-orcid":false,"given":"Scott A.","family":"Givan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin C.","family":"Zebley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin A.","family":"Youngblood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre J.","family":"Issa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Topper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3697-3798","authenticated-orcid":false,"given":"Stephen B.","family":"Baylin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria R.","family":"Baer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5665-946X","authenticated-orcid":false,"suffix":"Jr.","given":"Timothy J.","family":"Triche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casey L.","family":"O\u2019Connell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1535-9601","authenticated-orcid":false,"given":"Kirsten","family":"Gr\u00f8nb\u00e6k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8309-4767","authenticated-orcid":false,"given":"Peter A.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bneo.2026.100243_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clml.2021.07.031","article-title":"Myelodysplastic syndromes: a new decade","volume":"22","author":"Volpe","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.bneo.2026.100243_bib2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nrc.2016.112","article-title":"The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia","volume":"17","author":"Sperling","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.1016\/j.bneo.2026.100243_bib3","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nrc2047","article-title":"Myelodysplastic syndromes: the complexity of stem-cell diseases","volume":"7","author":"Corey","year":"2007","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"10.1016\/j.bneo.2026.100243_bib4","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1038\/s41375-019-0617-3","article-title":"The functional mechanisms of mutations in myelodysplastic syndrome","volume":"33","author":"Nagata","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.bneo.2026.100243_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2022.100805","article-title":"Different mechanisms of drug resistance to hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemia","volume":"61","author":"\u0160imoni\u010dov\u00e1","year":"2022","journal-title":"Drug Resist Updat"},{"issue":"5","key":"10.1016\/j.bneo.2026.100243_bib6","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-018-0085-4","article-title":"Myelodysplastic syndromes current treatment algorithm 2018","volume":"8","author":"Steensma","year":"2018","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.bneo.2026.100243_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2021.101245","article-title":"Management of patients with higher-risk myelodysplastic syndromes after failure of hypomethylating agents: what is on the horizon?","volume":"34","author":"Bewersdorf","year":"2021","journal-title":"Best Pract Res Clin Haematol"},{"issue":"16","key":"10.1016\/j.bneo.2026.100243_bib8","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1002\/cncr.25247","article-title":"Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy","volume":"116","author":"Jabbour","year":"2010","journal-title":"Cancer"},{"issue":"24","key":"10.1016\/j.bneo.2026.100243_bib9","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1200\/JCO.2011.35.8135","article-title":"Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure","volume":"29","author":"Pr\u00e9bet","year":"2011","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.bneo.2026.100243_bib10","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.clml.2013.07.007","article-title":"Poor outcome of patients with myelodysplastic syndrome after azacitidine treatment failure","volume":"13","author":"Duong","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"10.1016\/j.bneo.2026.100243_bib11","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.cell.2015.07.056","article-title":"DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts","volume":"162","author":"Roulois","year":"2015","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.bneo.2026.100243_bib12","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.cell.2015.07.011","article-title":"Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses","volume":"162","author":"Chiappinelli","year":"2015","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.bneo.2026.100243_bib13","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1158\/0008-5472.CAN-19-1696","article-title":"Activation of a subset of evolutionarily young transposable elements and innate immunity are linked to clinical responses to 5-azacytidine","volume":"80","author":"Ohtani","year":"2020","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.bneo.2026.100243_bib14","doi-asserted-by":"crossref","first-page":"9612","DOI":"10.18632\/oncotarget.3324","article-title":"Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS\/AML patients: a rationale for combined targeting of PD-1 and DNA methylation","volume":"6","author":"\u00d8rskov","year":"2015","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.bneo.2026.100243_bib15","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/leu.2013.355","article-title":"Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents","volume":"28","author":"Yang","year":"2014","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.bneo.2026.100243_bib16","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41571-019-0266-5","article-title":"The emerging role of epigenetic therapeutics in immuno-oncology","volume":"17","author":"Topper","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.bneo.2026.100243_bib17","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41568-019-0109-9","article-title":"Epigenetic therapy in immune-oncology","volume":"19","author":"Jones","year":"2019","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"10.1016\/j.bneo.2026.100243_bib18","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/s41375-018-0070-8","article-title":"Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes","volume":"32","author":"Daver","year":"2018","journal-title":"Leukemia"},{"issue":"24","key":"10.1016\/j.bneo.2026.100243_bib19","doi-asserted-by":"crossref","first-page":"5306","DOI":"10.1158\/1078-0432.CCR-22-1810","article-title":"Safety, outcomes, and T-cell characteristics in patients with relapsed or refractory MDS or CMML treated with atezolizumab in combination with guadecitabine","volume":"28","author":"O\u2019Connell","year":"2022","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.bneo.2026.100243_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.659625","article-title":"Response to hypomethylating agents in myelodysplastic syndrome is associated with emergence of novel TCR clonotypes","volume":"12","author":"Abbas","year":"2021","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.bneo.2026.100243_bib21","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1038\/s41375-021-01218-0","article-title":"Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies","volume":"35","author":"Stomper","year":"2021","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.bneo.2026.100243_bib22","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/PPO.0000000000000282","article-title":"DNA methyltransferase inhibitors in myeloid cancer: clonal eradication or clonal differentiation?","volume":"23","author":"\u00d8rskov","year":"2017","journal-title":"Cancer J"},{"key":"10.1016\/j.bneo.2026.100243_bib23","article-title":"Resistance to hypomethylating agents in myelodysplastic syndrome and acute myeloid leukemia from clinical data and molecular mechanism","volume":"11","author":"Zhao","year":"2021","journal-title":"Front Oncol"},{"issue":"24","key":"10.1016\/j.bneo.2026.100243_bib24","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.1093\/bioinformatics\/bts611","article-title":"SortMeRNA: fast and accurate filtering of ribosomal RNAs in metatranscriptomic data","volume":"28","author":"Kopylova","year":"2012","journal-title":"Bioinformatics"},{"issue":"8","key":"10.1016\/j.bneo.2026.100243_bib25","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/s41587-019-0201-4","article-title":"Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype","volume":"37","author":"Kim","year":"2019","journal-title":"Nat Biotechnol"},{"issue":"12","key":"10.1016\/j.bneo.2026.100243_bib26","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"10.1016\/j.bneo.2026.100243_bib27","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/978-1-60761-175-2_6","article-title":"Gene set enrichment analysis","volume":"563","author":"Tilford","year":"2009","journal-title":"Methods Mol Biol"},{"issue":"7","key":"10.1016\/j.bneo.2026.100243_bib28","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","article-title":"FeatureCounts: an efficient general purpose program for assigning sequence reads to genomic features","volume":"30","author":"Liao","year":"2014","journal-title":"Bioinformatics"},{"issue":"1","key":"10.1016\/j.bneo.2026.100243_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112016","article-title":"RNA mis-splicing drives viral mimicry response after DNMTi therapy in SETD2-mutant kidney cancer","volume":"42","author":"Li","year":"2023","journal-title":"Cell Rep"},{"issue":"3","key":"10.1016\/j.bneo.2026.100243_bib30","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nbt.2514","article-title":"Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples","volume":"31","author":"Cibulskis","year":"2013","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.bneo.2026.100243_bib31","article-title":"Calling somatic SNVs and indels with Mutect2","author":"Benjamin","year":"2019","journal-title":"bioRxiv"},{"issue":"9","key":"10.1016\/j.bneo.2026.100243_bib32","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/s41592-023-01943-7","article-title":"Unsupervised removal of systematic background noise from droplet-based single-cell experiments using CellBender","volume":"20","author":"Fleming","year":"2023","journal-title":"Nat Methods"},{"issue":"2","key":"10.1016\/j.bneo.2026.100243_bib33","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41587-023-01767-y","article-title":"Dictionary learning for integrative, multimodal and scalable single-cell analysis","volume":"42","author":"Hao","year":"2024","journal-title":"Nat Biotechnol"},{"issue":"13","key":"10.1016\/j.bneo.2026.100243_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2021.04.048","article-title":"Integrated analysis of multimodal single-cell data","volume":"184","author":"Hao","year":"2021","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.bneo.2026.100243_bib35","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41592-019-0654-x","article-title":"Orchestrating single-cell analysis with Bioconductor","volume":"17","author":"Amezquita","year":"2020","journal-title":"Nat Methods"},{"issue":"6","key":"10.1016\/j.bneo.2026.100243_bib36","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/s41592-021-01142-2","article-title":"TRUST4: immune repertoire reconstruction from bulk and single-cell RNA-seq data","volume":"18","author":"Song","year":"2021","journal-title":"Nat Methods"},{"issue":"1","key":"10.1016\/j.bneo.2026.100243_bib37","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-21246-9","article-title":"Inference and analysis of cell-cell communication using CellChat","volume":"12","author":"Jin","year":"2021","journal-title":"Nat Commun"},{"issue":"43","key":"10.1016\/j.bneo.2026.100243_bib38","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bneo.2026.100243_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fragi.2022.900028","article-title":"Immune senescence, immunosenescence and aging","volume":"3","author":"Lee","year":"2022","journal-title":"Front Aging"},{"key":"10.1016\/j.bneo.2026.100243_bib40","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2147\/JIR.S275595","article-title":"Reactive oxygen species: drivers of physiological and pathological processes","volume":"13","author":"Checa","year":"2020","journal-title":"J Inflamm Res"},{"issue":"20","key":"10.1016\/j.bneo.2026.100243_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20205002","article-title":"TGF-\u03b2 signaling in cellular senescence and aging-related pathology","volume":"20","author":"Tominaga","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.bneo.2026.100243_bib42","article-title":"Immunosenescence: molecular mechanisms and diseases","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.bneo.2026.100243_bib43","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-32552-1","article-title":"A new gene set identifies senescent cells and predicts senescence-associated pathways across tissues","volume":"13","author":"Saul","year":"2022","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.bneo.2026.100243_bib44","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"10.1016\/j.bneo.2026.100243_bib45","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41422-020-0343-4","article-title":"Immune checkpoint signaling and cancer immunotherapy","volume":"30","author":"He","year":"2020","journal-title":"Cell Res"},{"issue":"9","key":"10.1016\/j.bneo.2026.100243_bib46","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/nmeth.4380","article-title":"Simultaneous epitope and transcriptome measurement in single cells","volume":"14","author":"Stoeckius","year":"2017","journal-title":"Nat Methods"},{"issue":"1","key":"10.1016\/j.bneo.2026.100243_bib47","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-018-1603-1","article-title":"Cell Hashing with barcoded antibodies enables multiplexing and doublet detection for single cell genomics","volume":"19","author":"Stoeckius","year":"2018","journal-title":"Genome Biol"},{"issue":"23","key":"10.1016\/j.bneo.2026.100243_bib48","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.124928","article-title":"Human bone marrow assessment by single-cell RNA sequencing, mass cytometry, and flow cytometry","volume":"3","author":"Oetjen","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.bneo.2026.100243_bib49","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.exphem.2018.09.004","article-title":"The Human Cell Atlas bone marrow single-cell interactive web portal","volume":"68","author":"Hay","year":"2018","journal-title":"Exp Hematol"},{"issue":"1","key":"10.1016\/j.bneo.2026.100243_bib50","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-25960-2","article-title":"Confronting false discoveries in single-cell differential expression","volume":"12","author":"Squair","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.bneo.2026.100243_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.exphem.2018.03.003","article-title":"Senescent human hematopoietic progenitors show elevated expression of transposable elements and inflammatory genes","volume":"62","author":"Capone","year":"2018","journal-title":"Exp Hematol"},{"issue":"5","key":"10.1016\/j.bneo.2026.100243_bib52","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1128\/MCB.15.5.2672","article-title":"Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6","volume":"15","author":"Hirai","year":"1995","journal-title":"Mol Cell Biol"},{"issue":"9","key":"10.1016\/j.bneo.2026.100243_bib53","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1038\/sj.onc.1202466","article-title":"Comparison of the effectiveness of adenovirus vectors expressing cyclin kinase inhibitors p16(INK4A), p18(INK4C), p19(INK4D), p21(WAF1\/CIP1) and p27(KIP1) in inducing cell cycle arrest, apoptosis and inhibition of tumorigenicity","volume":"18","author":"Schreiber","year":"1999","journal-title":"Oncogene"},{"issue":"10","key":"10.1016\/j.bneo.2026.100243_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.107894","article-title":"An immunosuppressive subtype of senescent tumor cells predicted worse immunotherapy response in lung adenocarcinoma","volume":"26","author":"Fan","year":"2023","journal-title":"iScience"},{"issue":"1","key":"10.1016\/j.bneo.2026.100243_bib55","article-title":"Inflammation and aging: signaling pathways and intervention therapies","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.bneo.2026.100243_bib56","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s41375-022-01753-4","article-title":"Discriminating activities of DEAD-Box Helicase 41 from myeloid malignancy-associated germline variants by genetic rescue","volume":"37","author":"Kim","year":"2023","journal-title":"Leukemia"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2026.100243_bib57","doi-asserted-by":"crossref","first-page":"6691","DOI":"10.1182\/blood-2024-207573","article-title":"CDC2-like kinases (CLKs) inhibition as a novel targeted therapeutic strategy in myelodysplastic syndromes (MDS)","volume":"144","author":"Yang","year":"2024","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bneo.2026.100243_bib58","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.celrep.2017.06.067","article-title":"Integrative genomics identifies the molecular basis of resistance to azacitidine therapy in myelodysplastic syndromes","volume":"20","author":"Unnikrishnan","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.bneo.2026.100243_bib59","article-title":"S100A8\/A9 in inflammation","volume":"9","author":"Wang","year":"2018","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.bneo.2026.100243_bib60","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1038\/s41375-019-0397-9","article-title":"S100A9-induced overexpression of PD-1\/PD-L1 contributes to ineffective hematopoiesis in myelodysplastic syndromes","volume":"33","author":"Cheng","year":"2019","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.bneo.2026.100243_bib61","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10132788","article-title":"Myeloid-derived suppressor cells and mesenchymal stem\/stromal cells in myeloid malignancies","volume":"10","author":"Kapor","year":"2021","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.bneo.2026.100243_bib62","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","article-title":"The nature of myeloid-derived suppressor cells in the tumor microenvironment","volume":"37","author":"Kumar","year":"2016","journal-title":"Trends Immunol"},{"issue":"8","key":"10.1016\/j.bneo.2026.100243_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113006","article-title":"S100A8\/A9-alarmin promotes local myeloid-derived suppressor cell activation restricting severe autoimmune arthritis","volume":"42","author":"von Wulffen","year":"2023","journal-title":"Cell Rep"},{"issue":"7","key":"10.1016\/j.bneo.2026.100243_bib64","doi-asserted-by":"crossref","first-page":"4666","DOI":"10.4049\/jimmunol.181.7.4666","article-title":"Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells","volume":"181","author":"Sinha","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.bneo.2026.100243_bib65","doi-asserted-by":"crossref","DOI":"10.3389\/pore.2023.1611210","article-title":"Single-cell transcriptome analysis reveals the clinical implications of myeloid-derived suppressor cells in head and neck squamous cell carcinoma","volume":"29","author":"Jiang","year":"2023","journal-title":"Pathol Oncol Res"},{"issue":"7","key":"10.1016\/j.bneo.2026.100243_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2024.05.025","article-title":"Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors","volume":"42","author":"Espinosa-Carrasco","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bneo.2026.100243_bib67","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.clim.2016.01.008","article-title":"Roles of CD48 in regulating immunity and tolerance","volume":"164","author":"McArdel","year":"2016","journal-title":"Clin Immunol"},{"key":"10.1016\/j.bneo.2026.100243_bib68","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.75594","article-title":"C\/EBP\u03b4-induced epigenetic changes control the dynamic gene transcription of S100a8 and S100a9","volume":"11","author":"Jauch-Speer","year":"2022","journal-title":"Elife"},{"issue":"21","key":"10.1016\/j.bneo.2026.100243_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2023.08.022","article-title":"CD1 lipidomes reveal lipid-binding motifs and size-based antigen-display mechanisms","volume":"186","author":"Huang","year":"2023","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.bneo.2026.100243_bib70","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.it.2014.09.003","article-title":"\u03b3\u03b4 T cell surveillance via CD1 molecules","volume":"35","author":"Luoma","year":"2014","journal-title":"Trends Immunol"},{"issue":"6718","key":"10.1016\/j.bneo.2026.100243_bib71","doi-asserted-by":"crossref","DOI":"10.1126\/science.adl4492","article-title":"Epigenetic regulators of clonal hematopoiesis control CD8 T cell stemness during immunotherapy","volume":"386","author":"Kang","year":"2024","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.bneo.2026.100243_bib72","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/s41568-022-00450-9","article-title":"Exploiting senescence for the treatment of cancer","volume":"22","author":"Wang","year":"2022","journal-title":"Nat Rev Cancer"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000543?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000543?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:18:13Z","timestamp":1790687893000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328026000543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":72,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2950328026000543"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100243","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bone marrow immunosuppressive states associate with survival after guadecitabine and atezolizumab therapy in HMA-R\/R MDS","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100243","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100243"}}